Giovanni Fucà

31PUBLICATIONS
63CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Clinical midwiferyPredictive and prognostic markersApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (31)

|Apr 15, 2025
Navigating the Landscape of Resistance Mechanisms in Antibody-Drug Conjugates for Cancer Treatment.

Gloria Lalli, Ilaria Sabatucci, Mariachiara Paderno

|Jul 29, 2024
The clinical landscape of antibody-drug conjugates in endometrial cancer.

Giovanni Fucà, Ilaria Sabatucci, Mariachiara Paderno

|Aug 24, 2023
Adding fasting-mimicking diet to first-line carboplatin-based chemotherapy is associated with better overall survival in advanced triple-negative breast cancer patients: A subanalysis of the NCT03340935 trial.

Francesca Ligorio, Riccardo Lobefaro, Giovanni Fucà

|Apr 17, 2023
Prognostic significance of HER2-low status in HR-positive/HER2-negative advanced breast cancer treated with CDK4/6 inhibitors.

Emma Zattarin, Daniele Presti, Luigi Mariani

|Mar 19, 2022
Reinduction of an Anti-EGFR-based First-line Regimen in Patients with RAS Wild-type Metastatic Colorectal Cancer Enrolled in the Valentino Study.

Giovanni Fucà, Alessandra Raimondi, Michele Prisciandaro

|Feb 03, 2022
Ascites and resistance to immune checkpoint inhibition in dMMR/MSI-H metastatic colorectal and gastric cancers.

Giovanni Fucà, Romain Cohen, Sara Lonardi

Pageof 6

Frequent Collaborators

7 joint publications

Filippo Pietrantonio

4 joint publications

Claudio Vernieri

3 joint publications

Federica Morano

3 joint publications

Sara Lonardi